{
  "case_id": "case_001_diagnostic_odyssey",
  "primary_diagnosis": "CLN2 Disease (Late-Infantile Neuronal Ceroid Lipofuscinosis / Jansky-Bielschowsky Disease / Classic Late-Infantile Batten Disease) \u2014 enzymatically confirmed by TPP1 activity 0.8 nmol/hr/mg (<5% of normal). Diagnosis was originally established at age 9 by Dr. Amara Osei at Nationwide Children's Hospital (April 2021) but was LOST during military records transfer to North Carolina. The prior ASD diagnosis assigned at age 3.5 represents diagnostic overshadowing \u2014 early CLN2 behavioral manifestations were misclassified as autism, delaying recognition of a treatable neurodegenerative disease by approximately 5-6 years.",
  "confidence": 0.91,
  "differential_diagnoses": [
    {
      "diagnosis": "CLN2 disease with possible comorbid ASD",
      "probability": 0.91,
      "key_discriminator": "CLN2/TPP1 gene sequencing (sent June 2021, results pending in available records) would provide definitive molecular confirmation and genotype-phenotype correlation. The question of comorbid ASD versus CLN2-mimicked ASD features is clinically secondary but cannot be retrospectively resolved \u2014 the ADOS-2 score at age 3.5 (comparison score 7) is achievable entirely from early CLN2 cognitive decline without requiring true autism."
    },
    {
      "diagnosis": "CLN2 disease with primary mitochondrial disease co-contribution",
      "probability": 0.05,
      "key_discriminator": "The elevated lactate (2.8 mmol/L), elevated pyruvate (0.12 mmol/L), mtDNA VUS, and small basal ganglia lactate peak on MRS raise the question of dual pathology. However, the NORMAL lactate/pyruvate ratio (23.3) argues against primary respiratory chain deficiency. Functional studies on the mtDNA VUS or muscle biopsy with respiratory chain enzyme analysis would resolve this. Most likely represents secondary mitochondrial dysfunction from lysosomal lipofuscin accumulation."
    },
    {
      "diagnosis": "Variant late-infantile NCL (CLN5/CLN6/CLN7/CLN8)",
      "probability": 0.02,
      "key_discriminator": "These subtypes produce nearly identical clinical phenotype but would NOT cause isolated TPP1 deficiency. The specific TPP1 enzyme deficiency at 0.8 with all other lysosomal enzymes normal effectively excludes these variants. CLN2/TPP1 gene sequencing confirmation would be definitive."
    },
    {
      "diagnosis": "Laboratory error on TPP1 assay (false positive CLN2)",
      "probability": 0.005,
      "key_discriminator": "Quest Diagnostics CLIA-certified reference lab with phone notification of critical result, clinical phenotype independently predicted NCL before enzyme drawn, all other lysosomal enzymes normal (confirming sample integrity). Repeat TPP1 enzyme assay and/or CLN2/TPP1 gene sequencing would definitively exclude error."
    },
    {
      "diagnosis": "Autism Spectrum Disorder as sole diagnosis",
      "probability": 0.0,
      "key_discriminator": "Excluded with certainty. ASD is a static neurodevelopmental condition that does not cause: progressive cerebellar atrophy (35% volume loss), corticospinal tract disease (bilateral Babinski, sustained clonus), progressive loss of acquired motor skills (independent walking \u2192 wheelchair \u2192 Hoyer lift), macular lipofuscin deposits, photoparoxysmal EEG response, or TPP1 enzyme deficiency. The 68% decline in VB-MAPP scores over 14 months of intensive ABA therapy, unprecedented in the experience of therapists with 23 years and 190+ ASD clients, independently excludes ASD as sufficient explanation."
    }
  ],
  "key_evidence": [
    "TPP1 enzyme activity 0.8 nmol/hr/mg (normal 5.0-25.0, <5% of normal) \u2014 pathognomonic for CLN2 disease. Result from Quest Diagnostics reference laboratory (04/21/2021), CLIA-certified, with all other lysosomal enzymes normal, excluding other lysosomal storage diseases.",
    "Bilateral macular changes (orange-brown discoloration with surrounding retinal pallor) on fundoscopic exam by Dr. Osei (03/08/2021) \u2014 hallmark of lipofuscin accumulation in retinal neurons, characteristic of NCL and NOT seen in ASD, mitochondrial disease, or Rett syndrome.",
    "24-hour video EEG (04/05-06/2021): 11 seizures captured (3 absence, 7 myoclonic, 1 GTC), severe diffuse background slowing (5-6 Hz, expected 9-10 Hz), ROBUST photoparoxysmal response at 8-18 Hz (characteristic of NCL/progressive myoclonic epilepsy), and near-continuous spike-and-wave during sleep (ESES pattern). This EEG signature specifically discriminates NCL from ASD-associated epilepsy.",
    "MRI brain (04/07/2021): SEVERE cerebellar atrophy with 35% volume loss (92 cm\u00b3 vs expected 135-145 cm\u00b3), disproportionate to cerebral atrophy, with occipital-predominant cortical thinning and thalamic pulvinar signal changes \u2014 pattern specifically characteristic of CLN2 disease.",
    "Progressive multi-domain developmental regression incompatible with ASD: VB-MAPP milestone score declined 68.3% (31.5\u219210.0) over 14 months of intensive ABA therapy (672 hours). GMFM-88 declined from 68% to 22% over 25 months of PT. Equipment progression: independent walking \u2192 AFOs \u2192 posterior walker \u2192 wheelchair \u2192 Hoyer lift over 4 years. Speech: 25 words age 2 \u2192 5 words age 9 \u2192 <5 words age 11. ASD does not cause progressive loss of acquired motor skills.",
    "Developmental trajectory signature: normal milestones through 12 months \u2192 deceleration 12-24 months \u2192 plateau 24-36 months \u2192 continuous accelerating multi-domain regression from age 3 onward \u2014 this is the classic developmental signature of CLN2 disease with onset age 2-4 years, fundamentally incompatible with autism spectrum disorder.",
    "Multiple allied health professionals correctly identified the non-ASD nature years before physician diagnosis: PT Karen Lindstrom (2013) noted 'underlying neuromotor dysfunction beyond simple motor delay'; BCBA Jennifer Mallory (2016-2017) documented unprecedented regression across 40+ ASD clients; PT Sarah Lindgren (2020) wrote a landmark letter correctly listing NCL as the leading differential diagnosis with supporting clinical evidence."
  ],
  "recommended_next_steps": [
    "IMMEDIATE/EMERGENT: Confirm that the CLN2 diagnosis established by Dr. Osei in April 2021 is communicated to ALL current providers. The Nationwide Children's Hospital records (including TPP1 result, EEG, MRI, and diagnosis discussion) must be obtained and entered into Eli's current medical record. The mother's personal binder contains documentation that should be formally incorporated.",
    "IMMEDIATE: Evaluate Eli for cerliponase alfa (Brineura) enzyme replacement therapy eligibility. While disease is advanced at age 14, some stabilization may be achievable. Contact CLN2 treatment centers (University of Rochester, University of Hamburg) for evaluation \u2014 referral was initiated by Dr. Osei in June 2021 but status is unknown due to records transfer failure.",
    "URGENT: Obtain CLN2/TPP1 gene sequencing results (sent June 2021 per Record 8.5). If results are unavailable, re-order targeted TPP1 gene sequencing for: (a) molecular confirmation, (b) genotype-phenotype correlation (some mutations associated with protracted phenotype, consistent with Eli's survival to age 14), (c) definitive carrier testing for parents, (d) 25% recurrence risk counseling for future pregnancies.",
    "URGENT: Optimize seizure management \u2014 current levetiracetam 750mg BID + clobazam 5mg BID provides partial control. Neurology should consider additional agents while AVOIDING valproic acid (until mitochondrial contribution fully excluded) and carbamazepine/phenytoin (may worsen myoclonic seizures). Consider adjunctive CoQ10 and L-carnitine supplementation for secondary mitochondrial dysfunction.",
    "URGENT: Complete ophthalmology evaluation with OCT and electroretinography (ERG) to document degree of retinal degeneration and guide visual support needs.",
    "STANDARD: Parental carrier testing (both parents are obligate CLN2/TPP1 carriers) and formal genetic counseling regarding 25% recurrence risk for future pregnancies. Prenatal diagnosis is available.",
    "STANDARD: Comprehensive palliative care team engagement for symptom management, quality of life optimization, and family support. Psychology referral for grief counseling given the delayed diagnosis and its implications.",
    "STANDARD: Formal re-evaluation of the ASD diagnosis \u2014 list as 'possible comorbid, unconfirmed' rather than removing entirely, as retrospective differentiation between genuine ASD and CLN2-mimicked features is not possible.",
    "SYSTEMIC: Military health records system review \u2014 document the records transfer failure that caused loss of a confirmed, treatable diagnosis during PCS. Recommend EFMP (Exceptional Family Member Program) flagging for any future relocations to ensure continuity of specialized care."
  ],
  "dissenting_opinions": "All three specialists achieved unanimous consensus on CLN2 disease as the primary diagnosis across both rounds of debate, with final confidence scores of 0.90 (neurologist), 0.92 (developmental pediatrician), and 0.90 (geneticist). The Observer validated this convergence as genuinely evidence-driven by the pathognomonic TPP1 enzyme result rather than social influence or groupthink. Residual areas of non-consensus or acknowledged uncertainty include: (1) Whether genuine comorbid ASD exists alongside CLN2 \u2014 the developmental pediatrician argues the ADOS-2 findings are fully explainable by early CLN2 manifestations, while the neurologist and geneticist maintain Dr. Osei's classification of 'possible comorbid' as appropriately agnostic. This distinction has minor clinical relevance for communication support strategies. (2) Whether the mitochondrial DNA VUS and elevated lactate warrant independent investigation \u2014 the neurologist recommends CoQ10/carnitine supplementation as low-risk adjunctive therapy for secondary mitochondrial dysfunction, while the geneticist considers primary mitochondrial co-contribution extremely unlikely (<5% probability). (3) The geneticist identified a potentially atypical feature: walking achieved at 26 months per contemporaneous records versus 15 months claimed by later providers \u2014 this discrepancy may indicate earlier-than-typical CLN2 onset and has genotype-phenotype implications pending genetic sequencing results.",
  "reasoning_chain": "ROUND 1: All three specialists independently converged on CLN2 disease based on the pathognomonic TPP1 enzyme result (0.8 nmol/hr/mg, <5% of normal) combined with characteristic clinical features (progressive cerebellar atrophy, macular changes, photoparoxysmal EEG response, progressive multi-domain regression). Initial confidence: neurologist 0.92, developmental pediatrician 0.95, geneticist 0.92. All specialists identified the ASD diagnosis as diagnostic overshadowing but none formally questioned the CLN2 diagnosis with equivalent skepticism. \u2192 OBSERVER ROUND 1: Identified four biases: (1) premature closure \u2014 unanimous convergence triggered mandatory A-2.3 consensus challenge; (2) framing bias \u2014 all specialists followed the case's narrative arc to its confirmed conclusion; (3) confirmation bias in the developmental pediatrician \u2014 0.95 exceeded the geneticist's domain-relevant 0.92; (4) diagnostic momentum \u2014 asymmetric skepticism applied rigorously to ASD but not to CLN2. Observer mandated: framing independence exercises, symmetric A-006 application to CLN2, formal steelmanning of alternatives, and confidence decomposition per A-011. \u2192 ROUND 2: All three specialists addressed Observer feedback substantively. Key improvements: (a) Each performed framing independence exercise, confirming they would have reached NCL from pre-diagnostic Sections 1-2 data alone \u2014 validated by PT Sarah Lindgren's real-time correct identification of NCL in March 2020; (b) The geneticist formally evaluated TPP1 assay reliability and quantified false-positive probability at <0.5%; (c) The developmental pediatrician decomposed confidence into domain-specific (0.98) and cross-domain (0.92) components; (d) All specialists applied A-006 symmetrically to CLN2, finding it passes skepticism based on objective biochemical evidence unlike the ASD diagnosis which rested on behavioral interpretation; (e) The geneticist identified a genuine atypical feature (26-month walking age per contemporaneous records vs. 15-month claim by later providers); (f) Alternatives formally steelmanned: mitochondrial disease (normal L/P ratio argues against primary), CLN5/CLN6 variants (excluded by isolated TPP1 deficiency), Rett syndrome (excluded by macular changes, cerebellar pattern, and TPP1 deficiency), and lab error (<0.5% probability). Confidence adjusted: neurologist 0.92\u21920.90, developmental pediatrician 0.95\u21920.92, geneticist 0.92\u21920.90. \u2192 OBSERVER ROUND 2: Validated the convergence as genuinely evidence-driven. Noted coincidental confidence clustering (two specialists at exactly 0.90) but determined this reflected shared assessment of the single residual uncertainty (pending genetic sequencing) rather than mutual anchoring. Flagged minor calibration lag in developmental pediatrician's cross-domain confidence (aligned to Round 1 geneticist value rather than Round 2). Overall reasoning quality improved from 0.68 to 0.80. \u2192 FINAL SYNTHESIS: Institutional diagnosis of CLN2 disease at 0.91 confidence (weighted average of specialist assessments), reflecting the pathognomonic enzymatic confirmation tempered by pending genetic sequencing. The most critical finding is not the diagnosis itself \u2014 which was established in April 2021 \u2014 but that a CONFIRMED, TREATABLE diagnosis was lost in a military records transfer, potentially depriving Eli of disease-modifying therapy for 3+ additional years. The mother's personal record binder was more complete than any institutional medical record system."
}